Colorectal cancer (CRC) is one of the leading causes of cancer‐related death throughout the world.1 Cetuximab is an epidermal growth factor receptor (EGFR) monoclonal antibody that acts by blocking EGFR's extracellular domain, thereby negatively affecting cell growth and producing an antitumor effect. Here, EGFR is linked to colorectal carcinoma.